Regional and Systemic Strategies for Metastatic Malignant Melanoma

Mayo Clinic Proceedings

Volumn 64, Issue 7, 1989, Pages 852-860

  CREAGAN, EDWARD T ^a  

^a Division of Medical Oncology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BLEOMYCIN; CARMUSTINE; DACARBAZINE; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 2; LEVAMISOLE; LOMUSTINE; PLATINUM; SEMUSTINE; TUMOR NECROSIS FACTOR; VINBLASTINE; VINBLASTINE SULFATE;

ADVANCED CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIGHT EXPOSURE; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUNLIGHT;

EID: 0024445359     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(12)61759-5     Document Type: Article

References (36)

1. Vinblastine-bleomycin-platinum (VBD): a high response rate regimen in metastatic melanoma (abstract)
2. Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma
3. Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma
4. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma
5. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years'follow-up
6. High-dose chemotherapy with autologous marrow transplantation for malignant melanoma
7. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma
8. Isolation perfusion for malignant melanoma of the extremity: a review
9. The natural break points for primary-tumor thickness in clinical stage I melanoma (letter to the editor)
10. The role of elective lymph node dissection in melanoma: rationale, results, and controversies
11. “Prophylactic” lymph node dissection in melanoma: does it help? (editorial)
12. Current status and future prospects for adjuvant therapy of melanoma
13. Adjuvant therapy of cutaneous malignant melanoma: a critical review
14. Adjuvant levamisole improves survival and disease-free survival in patients with poor prognosis malignant melanoma (abstract)
15. Effects of biological response modifiers on effector cells with cytotoxic activity against tumors
16. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients
17. Recombinant leukocyte A interferon (rIFN-αA) in the treatment of disseminated malignant melanoma: analysis of complete and long-term responding patients
18. Clinical overview of alpha interferon: studies and future directions
19. Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer
20. Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma
21. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
22. Detection of cell surface and intracellular antigens by human monoclonal antibodies: hybrid cell lines derived from lymphocytes of patients with malignant melanoma
23. Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-l-aspartate (NSC-224131) plus l-alanosine (NSC-153353) in advanced malignant melanoma
24. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study
25. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy
26. Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome
27. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi
28. The dysplastic nevus syndrome: our definition
29. Surgical treatment of distant metastatic melanoma: indications and results
30. Surgery as palliative treatment for distant metastases of melanoma
31. Malignant melanoma with unknown primary site
32. Occult melanoma in lymph nodes detected by antiserum to S-100 protein
33. Which pigmented moles should be removed in prepubertal-age children? A case for a conservative approach
34. Spitz naevi and malignant melanomas of childhood and adolescence
35. Malignant melanoma and pregnancy